Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lisaftoclax plus hypomethylating agents in intermediate- and high-risk MDS (real-world, single-arm, phase 4)
ChiCTR2600123533Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Dalian Medical University
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lisaftoclax in myelodysplastic syndrome (MDS), sponsored by The First Affiliated Hospital of Dalian Medical University. Primary endpoint: Composite Complete Remission Rate (cCRR). Planned start Apr 2026; status: not yet recruiting.
02
Drugs
lisaftoclax
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2600123533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600123533.